Evidence map›Paper›PMID 34604446›Full record

ArticleBio-protocol2021

Measurement of LRRK2 Kinase Activity by Proximity Ligation Assay.

Matthew T Keeney, Eric K Hoffman, Timothy J Greenamyre, Roberto Di Maio

Open access · greenAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Bio-protocol, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
1.5field-weighted citation impact, top 15% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 14 citations in OpenAlex.

  1. Article
  2. Article
  3. Review
  4. Article
  5. Article
  6. Article
  7. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 2 institutions in 1 country.

Matthew T KeeneyPittsburgh Institute for Neurodegenerative Diseases, Pittsburgh, PA, USA.
Eric K HoffmanPittsburgh Institute for Neurodegenerative Diseases, Pittsburgh, PA, USA.
Timothy J GreenamyrePittsburgh Institute for Neurodegenerative Diseases, Pittsburgh, PA, USA.
Roberto Di MaioPittsburgh Institute for Neurodegenerative Diseases, Pittsburgh, PA, USA.
Institute for Neurodegenerative Disorders · USUniversity of Pittsburgh · US

Funding

alpha-Synuclein Inhibition of Mitochondrial Protein ImportR01NS095387 · NINDS · UNIVERSITY OF PITTSBURGH AT PITTSBURGH · PI GREENAMYRE, J TIMOTHY · 2015 to 2019
$2.2M
Role of LRRK2 in idiopathic Parkinson's diseaseR01NS100744 · NINDS · UNIVERSITY OF PITTSBURGH AT PITTSBURGH · PI GREENAMYRE, J TIMOTHY · 2017 to 2021
$1.7M
A slowly progressive, endogenous synucleinopathy model of Parkinson's diseaseR21ES027470 · NIEHS · UNIVERSITY OF PITTSBURGH AT PITTSBURGH · PI GREENAMYRE, J TIMOTHY · 2017 to 2018
$427k
NIEHS NIH HHS R21 ES027470NINDS NIH HHS R01 NS095387NINDS NIH HHS R01 NS100744
6 · The paper itself

Abstract

Missense mutations in leucine rich-repeat kinase 2 (LRRK2) cause forms of familial Parkinson's disease and have been linked to 'idiopathic' Parkinson's disease. Assessment of LRRK2 kinase activity has been very challenging due to its size, complex structure, and relatively low abundance. A standard in the field to assess LRRK2 kinase activity is to measure the level of substrate phosphorylation (pThr73-Rab10) or autophosphorylation of serine 1292 (

Indexed as

FluorescenceLRRK2Parkinson’s diseaseProximity ligation assay

Identifiers

PMID34604446
PMCPMC8443460
OpenAlexW3196512331

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.